AstraZeneca PLC (AZNCF)
| Previous close | 138.24 |
| Open | 135.62 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 135.62 - 135.62 |
| 52-week range | 118.16 - 153.10 |
| Volume | |
| Avg. volume | 3,020 |
| Market cap | 210.249B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 35.50 |
| EPS (TTM) | 3.82 |
| Earnings date | N/A |
| Forward dividend & yield | 2.86 (2.07%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
ZacksAstrazeneca (AZN) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Fool.co.ukI don’t care how much FTSE bosses are paid as long as they make me rich!
Facing accusations of greed, the pay packages of FTSE CEOs are back in the headlines. But our writer takes a more relaxed view, on one condition. The post I don’t care how much FTSE bosses are paid as long as they make me rich! appeared first on The Motley Fool UK.
Business WireIMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
